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Abstract
Rationale Orexins play a key role in the maintenance of
alertness and are implicated in the modulation of diverse
physiological processes, including cognitive function.
Almorexant, a dual orexin receptor antagonist, transiently
and reversibly blocks the action of orexin peptides at both
OX1 and OX2 receptors and increases time spent in rapid
eye movement (REM) and non-REM sleep.
Objectives We explored the direct effects on learning and
memory of single and repeated administration of almorex-
ant in rats.
Methods Following administration of high doses of almor-
exant (300 mg/kg, p.o.), scopolamine (0.8 mg/kg, i.p.),
combination almorexant-scopolamine, or vehicle alone, rats
were trained on a Morris water maze spatial navigation
task, or on a passive avoidance task.
Results Rats treated with almorexant learned the spatial
navigation task with similar efficacy as vehicle-treated
animals. After 4 days, almorexant—but not vehicle-treated
rats had established spatial memory; after 8 days, spatial
memory had been established in both vehicle—and
almorexant-treated rats. Scopolamine-treated rats failed to
learn the spatial task. Both vehicle—and almorexant—but
not scopolamine-treated rats demonstrated passive avoid-
ance learning. Almorexant did not ameliorate scopolamine-
induced impairment of learning in either task.
Conclusions Rats treated with almorexant are fully capable
of spatial and avoidance learning.
Keywords Almorexant.ACT-078573.Orexin.Rat.
Morris water maze.Spatial learning.
Passive avoidance learning.Scopolamine
Introduction
The amount of time spent in rapid eye movement (REM)
and non-REM (NREM) sleep exerts an influence on
cognitive processes in animals and humans. Controversially
debated (Genzel et al. 2009) and not yet fully understood,
this phenomenon has become known as sleep-dependent
memory consolidation (Maquet 2001; Stickgold 2005;
Walker and Stickgold 2006).
Orexin peptides (orexin-A [or hypocretin-1] and orexin-B
[or hypocretin-2]) play a primary role in regulating sleep and
alertness (reviewed in de Lecea and Sutcliffe 2005;K i l d u f f
and Peyron 2000;O h n oa n dS a k u r a i2008; Saper et al.
2005), which has direct functional implications for diverse
brain functions including learning and memory (Akbari et al.
2008;A k b a r ie ta l .2006, 2007; Aou et al. 2003;J a e g e re ta l .
2002; Smith and Pang 2005; Wayner et al. 2004). Orexin
neurons project to various brain regions including the basal
forebrain (Peyron et al. 1998), an area implicated in the
regulation of wakefulness and cortical desynchronization
(Jones 2004), which contains cholinergic neurons that are
active during waking and REM sleep (Lee et al. 2005). The
cholinergic system is well known for its role in learning and
memory, while its degeneration—as occurs in elderly people
and patients with Alzheimer's disease—correlates with
cognitive decline (Perry et al. 1981).
Almorexant is a dual orexin receptor antagonist, which
reversibly blocks signaling of orexin-A and orexin-B pep-
tides. Oral administration of almorexant elicits somnolence
without cataplexy in healthy rats, dogs, and humans when
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(Brisbare-Roch et al. 2007). In the rat, almorexant maintains
the natural architecture of sleep by decreasing active
wakefulness and increasing the time spent in REM and
NREM sleep in physiological proportion. This is in contrast
to benzodiazepine receptor agonists, which tend to increase
the time spent in quiet wakefulness and NREM sleep while
shortening the time spent in REM sleep (Brisbare-Roch et al.
2007). The sleep state elicited by almorexant is easily
surmountable and can be maintained upon repeated admin-
istration (Brisbare-Roch et al. 2007).
Here, we investigated the impact of high doses of
almorexant on cognitive function in rodents using (1) a Morris
water maze (MWM) spatial navigation (reference memory)
task (Morris 1981, 1984), which requires rats to learn how to
locate a water-submerged escape platform with the help of
extra-maze cues and (2) a test of passive avoidance (PA)
learning, which requires rats to suppress a specific behavior in
order to avoid an aversive stimulus (for a review, see Byrne
2003). Studies using virtual versions of the MWM task in
humans support the assumption that spatial learning in rodents
and humans involves similar principles (Hamilton et al. 2002).
Both spatial navigation in the MWM task and PA learning are
well known to be sensitive to pharmacological manipulations
of the cholinergic system (Lindner et al. 2006; Riekkinen et
al. 1995, 1996;W h i s h a w1985) ,a n dw eu s e dt h em u s c a r i n i c
cholinergic receptor antagonist scopolamine as a reference
drug to impair memory.
Materials and methods
Subjects
Each MWM experiment was conducted on 24 male Long-
Evans rats (Crl:LE, Charles River, Raleigh, NC, USA) of 16–
18 weeks of age. Sixty-four male Wistar rats (RccHan:WIST,
Harlan Laboratories, Netherlands) of 12 weeks of age were
tested on a PA task.
All rats were maintained in groups of four in a
temperature—and humidity-controlled room with a 12-
h light–dark cycle, and with food and water provided ad
libitum. Experiments were carried out between 8 a.m. and 5
p.m.
Morris water maze
MWM testing followed established procedures (Morris 1981,
1984). A circular white pool (diameter 1.8 m; height 60 cm)
w a sf i l l e d4 0c md e e pw i t hw a t e rt h a tw a sm a i n t a i n e da t2 6 ±
1°C and made opaque by the addition of an opacifier (an
aqueous acrylic emulsion; Acusol, Rohm & Haas, Land-
skrona, Sweden). A white plastic escape platform (diameter
11 cm) was placed in the center of one of the four equal-area
quadrants of the pool.
In “cued” trials, the escape platform extended 1.5 cm above
the water surface and the border of the escape platform was
colored black to increase visibility. In “uncued” (referring to
proximal cues) trials, the escape platform was submerged
1.5 cm below the water surface. In “probe” trials, no escape
platform was present. The pool was surrounded by large,
dissimilar, distal visual cues p l a c e do nt h ew a l l st oa s s i s t
allocentric orientation and spatial navigation. During trials,
behavioral variables including the latency to climb the escape
platform (escape latency), swim speed (average velocity),
number of completed circles swum (pool circlings), and time
spent by the rat in the water maze quadrants (time in quadrant)
w e r em e a s u r e du s i n gav i d e ot r a c k i n gs y s t e m( H V SI m a g e ,
Buckingham, UK). Time during which rats were not actively
swimming (i.e., floating) was excluded from the calculation of
velocity.
Eachcuedoruncuedtrialbeganbygentlyreleasingaratinto
the water facing the wall of the pool and ended when the rat
climbedtheescapeplatformorafteracut-offof60s,whichever
came first. When the rat did not reach the escape platform
within 60 s, the experimenter guided the rat to the escape
platform. After completion of a trial, rats were allowed to stay
on the escape platform for approximately 15 s for spatial
orientation. Rats were gently removed from the escape
platform, dried with a towel and kept in holding cages. At the
end of each day's spatial training, rats were returned to their
home cages.
For a timeline of the experiments, see Fig. 1a.7 2hb e f o r e
the first uncued trial, rats performed a total of six cued trials,
analyzed in two blocks of three trials denoted as C1 and C2;
this allowed the animals to become familiar with the
experimental set-up and procedures. Rats were subsequently
trained for spatial navigation using 24 uncued acquisition
trials, analyzed in eight daily blocks of three trials (U1–U4 in
the first week and U5–U8 in the second week). 24±2 h after
the first and second weeks’ last uncued trial, rats were tested
for memory retention in two 30 s probe trials (P1 and P2) in
which no escape platform was present. The time spent by rats
in the “target quadrant” (the pool quadrant that had contained
the escape platform during the spatial training period) relative
to the other quadrants was analyzed as a measure of memory
retention. The last probe trial P2 was followed by two cued
trials, analyzed in one trial block (C3); these trials served as
control measures for motivation and sensorimotor function.
The escape platform location was varied across cued trials.
In uncued trials, escape platform location was varied across
subjects but kept constant for each rat. To prevent the
possibility of egocentric orientation, the location of the rat’s
entry into the pool was varied across trials. During probe trials,
inordertokeepthedistancebetweenthelocationofarat's entry
into the pool and the previously trained escape platform
146 Psychopharmacology (2010) 212:145–154location at a constant and maximal length, the position of
entry into the pool was assigned to the quadrant opposite the
target quadrant.
Passive avoidance
The “GEMINI” avoidance system with software part 6810-
0006-C, equipped with the “AirStim” option (San Diego
Instruments, San Diego, CA, USA), was used for tests of
step-through type PA learning. One unit consisted of two
compartments with inner dimensions of 25 (width)×20
(depth)×17 cm (height). The walls were acrylic; the floor
consisted of stainless steel grids (diameter 7 mm), 14 per
compartment, spaced 9 mm apart and aligned from front to
back. An 8.5 cm (width)×7.6 cm (height) rectangular
opening at grid floor level connected both compartments.
This opening could be closed by a stainless steel gate. The
front wall of each compartment consisted of a door that
could be opened to place a rat into or take it out of the
compartment. The location of the rat was detected by infra-
red photoelectric beams, eight per compartment, positioned
13 mm above the grid floor. An LED house light was
centered in the ceiling of each compartment, and supplied
650 lx at grid-floor level.
Air pulse stimulation was chosen as the aversive stimulus,
and was delivered from two aluminum tubes (length 24.5 cm,
external diameter 6.5 mm), one at the front and one at the back
wall of each compartment, positioned 19 mm above the grid
floor, and perforated at the vertical center with nine 2.5×
0.8 mm holes spaced 2.5 cm apart. Air was delivered to the
system from a compressed air bottle at a static pressure of
379.2 kPa (55 psi), which was set for each compartment
separately using a regulator (Model R07, Norgren, Littleton,
CO, USA), yielding a pressure of 322.7 kPa (46.8 psi) at
presentation of air. Air was delivered at 3,160 cm
3/s into the
Tygon tubing (model AAG00007, Saint-Gobain Performance
Plastics, Akron, OH, USA; inner diameter 3.2 mm) that
connected the regulator to the stimulus delivery tubes. When
stimulation was initiated, three pulses of air were applied,
each 0.5 s in duration and with 0.5 s separating each pulse
(offset to onset). The actual pressure settings were sufficient to
initiate a startle response.
The operant conditioning phase consisted of a single trial
that began after a rat was gently placed into the right-hand
compartment of a GEMINI unit (with front doors and gate
closed, and lights turned off). After an acclimation period of
120 s, the compartment in which the rat was located was
illuminated and the gate to the left-hand, unilluminated
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Fig. 1 a Experimental design illustrating the 15-day training and
assessment protocol of Morris water maze (MWM) experiments. A
tick mark indicates that rats received drug treatment on the respective
day. b Spatial learning: latency in the MWM task to localize,
approach, and climb an escape platform that was visible (cued trials,
C1–C2; C3) or hidden (uncued trials, U1–U8). Rats were treated with
vehicle only (open circles), almorexant (triangles), or scopolamine
(squares) before daily spatial training sessions. Trial blocks C1–C2
and U1–U8 include three trials per rat; trial block C3 includes two
trials. Note that retention tests (probe trials P1 and P2, in open
triangles) are depicted only to illustrate the order of trial blocks (for
results on probe trials, see Fig. 2). Data are presented as mean±
standard error of the mean with eight rats per treatment group
Psychopharmacology (2010) 212:145–154 147compartment was opened. Step-through latency, i.e., the time
until the rat completely stepped through into the left-hand
compartment, was recorded. Once the rat stepped through, the
gate was closed and, after a delay of 1 s, air pulses were applied
t ot h er a t .T h er a tw a sa l l o w e dt os t a yi nt h el e f t - h a n d
compartment to associate the aversive event with the environ-
ment, after which it was returned to the home cage. Rats that
did not step through within 600 s during the conditioning phase
were excluded from the experiment.
The test phase, performed 24 h later, consisted of a
single trial identical to the conditioning phase trial with the
exception that no aversive stimulus was applied when the
rat stepped through. An increase in step-through latency is
considered to be an indicator of memory retention (i.e.,
conditioning success).
Drug treatment
Rats were assigned to one of four drug treatments:
1. Vehiclegroupsreceivedoraltreatmentwitha water-based
solution containing 0.25% methyl cellulose (Methocel®
MC, Fluka/Sigma-Aldrich Chemie GmbH, Steinheim,
Germany) and intraperitoneal treatment with saline (NaCl
0.9%, B. Braun Medical AG, Switzerland).
2. Almorexant groups received oral treatment with almor-
exant hydrochloride (Actelion Pharmaceuticals Ltd,
Allschwil, Switzerland) in a water-based solution
containing 0.25% methyl cellulose, at a dose of
300 mg/kg (calculated as almorexant free base), and
intraperitoneal treatment with saline.
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Fig. 2 Spatial memory retention: proportion of time spent by rats in
the quadrants of the Morris water maze (MWM) during probe trials.
After rats had been repeatedly trained on a MWM task under either
vehicle, almorexant, or scopolamine treatment (see Fig. 1b), spatial
memory retention tests were conducted 24±2 h after a the first week's
(P1) and b the second week's (P2) last uncued trial block. No drug
treatment was given at P1; drug treatment was given at P2 as on
preceding days of spatial training (for a timeline, see Fig. 1a). Black
bars represent the target quadrant (the quadrant that had contained the
escape platform during the spatial training period); the bar on the left
and the two bars on the right of each black bar represent the
quadrants to the left, right, and opposite the target quadrant,
respectively. Asterisks indicate that the proportion of time spent in
the target quadrant was significantly above the chance rate of 25%
(p<0.05, T test for single means against a constant), i.e., spatial
memory had been established. Data are presented as mean±standard
error of the mean with eight rats per treatment group. Inserts show
representative plots (top view) of individual swim paths of one rat for
each treatment group and probe trial. In these examples, the start
location was in the north–west quadrant of the pool, and the platform
had formerly been located in the south–east quadrant of the pool
(indicated by small circle for illustration purposes only; note that no
platform was present in probe trials)
148 Psychopharmacology (2010) 212:145–1543. Scopolamine groups received oral treatment with a water-
based solution containing 0.25% methyl cellulose and
intraperitoneal treatment withscopolamine hydrobromide
trihydrate (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany) in saline, at a scopolamine dose of 0.8 mg/kg.
4. Combination (combo) groups received oral treatment
with almorexant hydrochloride in a water-based
solution containing 0.25% methyl cellulose, at an
almorexant dose of 300 mg/kg, and intraperitoneal
treatment with scopolamine hydrobromide trihydrate
in saline, at a scopolamine dose of 0.8 mg/kg.
The first MWM experiment included a vehicle group, an
almorexant group, and a scopolamine group, whereas the
follow-up experiment included an almorexant group, a
combo group, and a scopolamine group. The PA experi-
ment included all four treatments.
In MWM experiments, treatment was given on every day
of spatial training and on the day of the second probe trial
P2; in order to control for state dependency, no treatment
was given on the day of the first probe trial P1 (Fig. 1a). In
the PA experiment, treatment was given once before the
acquisition trial.
All treatments were administered with 5 ml/kg. In all
experiments, treatments were administered orally and intra-
peritoneally 60 and 30 min, respectively, before task perfor-
mance based on the pharmacokinetic and pharmacodynamic
properties of almorexant (Brisbare-Roch et al. 2007)a n d
published practice for scopolamine (e.g., McNamara and
Skelton 1992; Riekkinen et al. 1996).
Statistical analyses
In order to determine statistically significant differences in
escape latency, average velocity, and pool circlings in the
MWM test, an analysis of variance (repeated measures two-
way analysis of variance (ANOVA) for C1–C2, and U1–U8;
one-way ANOVA for C3) was employed. A T test comparing
single means against a constant was used to determine if the
proportion of time spent in the target quadrant of the MWM
was significantly different from the chance rate of 25%.
AWilcoxon-matchedpairs testwasemployed forthe PAtest
to determine statistically significant intra-individual differences
in step-through latency between the conditioning and test
phases. A Mann–Whitney test was employed to determine
significant differences in step-through latency between drug
treatment groups.
Statistical testing was performed using statistical soft-
ware (Statistica, version 6, StatSoft Inc., Tulsa, OK, USA;
and Prism, version 5.01, GraphPad Software, Inc., USA)
with differences considered statistically significant at p<
0.05. Data are presented as mean±standard error of the
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Fig. 3 Spatial memory reten-
tion: proportion of time spent
by rats in the quadrants of the
Morris water maze during probe
trials. See legend of Fig. 2 for
details with exception of the
following: rats were treated with
either almorexant alone, both
almorexant and scopolamine
(“combo”), or scopolamine
alone. In the examples of indi-
vidual swim paths, the start
location was in the south–west
quadrant of the pool, and the
platform had formerly been lo-
cated in the north–east quadrant
of the pool
Psychopharmacology (2010) 212:145–154 149mean with eight (MWM) or 14–16 (PA) rats per treatment
group.
Results
Spatial learning in MWM
Latency to localize, approach, and climb the escape platform in
cuedanduncuedtrialswasassessedusinga15-daytrainingand
assessment protocol (Fig. 1a). Rats improved escape latency
over time in both cued (C1–C2, F(1,21)=8.2, p<0.01) and
uncued trials (U1–U8, F(7,147)=8.7, p<0.001) (Fig. 1b).
Thus, rats were able to improve task performance over time
independently of whether the platform was visible. No
treatment effect on escape latency was found for cued trials
(C1–C2, F(2,21)=2.0, p=0.2; C3, F(2,21)=0.5, p=0.6)
(Fig. 1b), and no statistically significant interaction was
observed between treatment and time for initial cued trials
(C1–C2, F(2,21)=0.5, p=0.6) (Fig. 1b), suggesting that
treatment groups did not differ in their ability to solve the
cued task variant.
During uncued trials, however, treatment groups differed
(U1–U8, F(2,21)=9.4, p<0.01) (Fig. 1b). The escape latency
of scopolamine-treated rats, although it decreased over time,
was higher compared with latencies of both of the other
treatment groups throughout the entire time course. The
analysis consistently failed to demonstrate a statistically
significant interaction between treatment and time (U1–U8,
F(14,147)=1.1, p=0.4) (Fig. 1b). In contrast to scopolamine-
treated rats, both vehicle—and almorexant-treated rats suc-
cessfully learned the spatial task; after 8 days of spatial
training, they attained escape latencies similar to those
observed in cued trials.
Spatial memory retention in MWM
Spatial memory retention was considered established when
the proportion of time spent in the target quadrant during
probe trials was significantly above the chance rate of 25%.
In probe trial P1 (Fig. 2a) conducted 24±2 h after the first
week's last uncued trial block (under no drug treatment), only
almorexant-treated rats had established spatial memory (T=4.9,
df=7, p<0.01), whereas vehicle—and scopolamine-treated rats
failed to establish spatial memory (vehicle group, T=1.7,df=7,
p=0.1; scopolamine group, T=−2.4, df=7, p=0.05).
In probe trial P2 (Fig. 2b) conducted 24±2 h after the
second week's last uncued trial block (under drug treat-
ment), both vehicle—and almorexant-treated rats were
found to have established spatial memory (vehicle group,
T=3.3, df=7, p<0.05; almorexant group, T=3.3, df=7, p<
0.05), whereas the scopolamine group failed to establish
spatial memory (T=−0.5, df=7, p=0.6).
In a follow-up MWM experiment, the effect of the
combination of almorexant and scopolamine was tested.
Here, we only report results on spatial memory retention. In
probe trials P1 and P2 (Fig. 3), only almorexant-treated rats
had established spatial memory (P1, T=2.7, df=7, p=0.03;
P2, T=7.7, df=7, p<0.001), whereas combo—and
scopolamine-treated rats failed to establish spatial memory
(combo group, P1, T=−1.1, df=7, p=0.3, P2, T=1.0, df=7,
p=0.3; scopolamine group, P1, T=−0.3, df=7, p=0.8, P2,
T=−0.1, df=7, p=0.9).
Control measures in MWM
To exclude the possibility that disturbances in sensori-
motor function or motivation may have interfered with
testing, we analyzed swim velocity and number of pool
circlings. For initial cued trials, no statistically significant
difference was found in either average velocity (C1–C2,
F(2,21)=1.2, p=0.3) (Fig.4a)o rp o o lc i r c l i n g s( C 1 –C2, F
(2,21)=0.3, p=0.7) (Fig. 4b) across treatment groups,
suggesting that treatment groups were comparable at the
beginning of the experiment. As rats learned over time to
escape onto the visible platform, pool circlings remained
unchanged (C1–C2, F(1,21)=1.8, p=0.2) (Fig. 4b)b u t
average velocity increased (C1–C2, F(1,21)=9.4, p<0.01)
(Fig. 4a) to levels similar to those observed in vehicle—
and almorexant-treated rats at the beginning of spatial
training.
During performance of the spatial task, treatment groups
differed in both average velocity (U1–U8, F(2,21)=11.5, p
<0.001) (Fig. 4a) and pool circlings (U1–U8, F(2,21)=
14.0, p<0.001) (Fig. 4b). Swimming in circles, as opposed
to the navigation strategy in which rats learn to use spatial
cues to localize the escape platform, may serve as an
alternative behavioral strategy that increases the probability
of hitting the submerged escape platform by chance. We
observed that rats swimming in circles, often in combina-
tion with thigmotaxis, swam faster than rats appearing to
employ the navigation strategy (data not shown). A
consistently higher number of pool circlings and, possibly
as result, consistently higher swim velocities were observed
for scopolamine-treated rats compared with almorexant—or
vehicle-treated rats. Time effects were observed for both
average velocity (U1–U8, F(7,147)=4.9, p<0.0001)
(Fig. 4a) and pool circlings (U1–U8, F(7,147)=3.2, p<
0.01) (Fig. 4b).
No interactions between treatment and time were observed
for both average velocity and pool circlings (C1–C2, average
velocity, F(2,21)=0.2, p=0.8, pool circlings, F(2,21)=0.5, p=
0.6; U1–U8, average velocity, F(14,147)=1.0 p=0.4, pool
circlings, F(14,147)=0.6, p=0.9) (Fig. 4). In final cued trials,
treatment affected average velocity (C3, F(2,21)=10.4, p<
0.001) (Fig. 4a) but not pool circlings (C3, F(2,21)=1.0, p=
150 Psychopharmacology (2010) 212:145–1540.4) (Fig. 4b); the presence of a visual cue thus diminished
pool circlings but did not return average velocity to normal
values in scopolamine-treated rats.
Avoidance memory retention in PA
Memoryretentionwasconsideredestablishedwhenstep-through
latency during the conditioning phase was statistically different
from step-through latency during the test phase. Memory
retention was intact in both vehicle-treated rats (p<0.05) and
almorexant-treated rats (p<0.01) but this was not the case for
either scopolamine—(p=0.6) or combo-treated rats (p=0.1).
In the test phase, almorexant-treated rats did not differ in
step-through latency from vehicle-treated rats (p=0.2) but both
scopolamine—(p<0.05) and combo-treated rats (p<0.01) did
(Fig. 5).
Discussion
Our results show that rats treated with repeated doses of
almorexant are fully capable of establishing spatial memory
in a MWM spatial navigation task that is sensitive to agents
which impair hippocampus-dependent declarative learning.
After 4 days of spatial training, only almorexant-treated rats
had established spatial memory; after 8 days of spatial
training, both vehicle—and almorexant-treated rats demon-
strated spatial memory retention. In contrast, rats treated
with scopolamine failed to learn the task and did not show
spatial memory retention after either 4 or 8 days of spatial
training. The result of the first memory retention test after
4 days of spatial training suggests that almorexant
facilitated memory encoding and/or consolidation processes
during the spatial acquisition phase and thus may have
accelerated establishment of spatial memory. However,
almorexant did not ameliorate the scopolamine-induced
impairment of spatial memory. The fact that rats in the
almorexant group demonstrated memory retention under
undrugged conditions during the first memory retention test
conducted after 4 days of spatial training suggests that the
memory retrieval process was not state dependent, i.e., rats
did not need to be under the influence of almorexant to
retrieve memory. The results of the second memory
retention test conducted under drug influence after 8 days
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Psychopharmacology (2010) 212:145–154 151of spatial training suggest that almorexant does not interfere
with retrieval of spatial memory.
Both vehicle-treated rats and almorexant-treated rats were
able to learn the passive avoidance task; in contrast,
scopolamine-treated rats and rats treated with the combination
of almorexant and scopolamine were not able to learn the task.
Thus rats treated with almorexant are fully capable of
avoidance learning in a PA task that is sensitive to agents
which impair associative learning, which is in line with our
MWM findings.
Almorexant increases the time spent in NREM and REM
sleep. Over a 12 h night, rats treated with almorexant at a dose
of 300 mg/kg spent 41.1% of the time in NREM sleep and
7.9% in REM sleep versus 31.8% in NREM sleep and 4.5% in
REM sleep for vehicle-treated rats (Brisbare-Roch et al. 2007).
This increase in the proportion of NREM and REM sleep may
contribute to beneficial effects on learning and memory.
Although controversially discussed (Genzel et al. 2009),
evidence has accumulated over the last decade in favor of
sleep-dependent learning and memory processes (reviewed in
Born et al. 2006; Stickgold 2005; Stickgold and Walker 2005;
Walker and Stickgold 2006; Wayner et al. 2004). Functional
imaging data from healthy human subjects indicates that sleep
is implicated in the consolidation of declarative memory (Gais
et al. 2007; Sterpenich et al. 2007). It has been suggested that
NREM sleep is crucial for declarative memory processes
(Plihal and Born 1999; Rasch et al. 2009). On the other hand,
REM sleep might be particularly beneficial for procedural
memory (Rasch et al. 2009; Smith 1995).
The cholinergic system in the basal forebrain, hippocampus,
amygdala, and neocortex is well known to be implicated in
memory processing (Everitt and Robbins 1997) and high
cholinergic tone is considered a prerequisite for efficient
encoding of memories during wakefulness (Bartus et al. 1982;
Rasch et al. 2006). The muscarinic cholinergic receptor
antagonist scopolamine has been widely used to induce the
cognitive deficits associated with cholinergic hypofunction.
Pharmacological blockade of central muscarinic receptors has
been reported to induce short-term amnestic effects for a
variety of cognitive tasks in normal human subjects,
nonhuman primates, and rodents (McNamara and Skelton
1992, and references therein).
Our results are in line with literature reports indicating that
cholinergicantagonists impair spatial learninginthe MWM but
not cue learning (Whishaw 1985). The scopolamine amnesia
model has been criticized for non-mnemonic side effects
(Beiko et al. 1997;T e r r y2006), which might be held
responsible for the increased pool circlings and swim velocity
that we observed with scopolamine treatment. However,
scopolamine-induced spatial memory deficits have been
demonstrated even under conditions that prevent e dd r u gs i d e
effects by utilizing a novel delayed matching to position water
maze task (von Linstow Roloff et al. 2007).
Incontrast tothe deficits inducedbycholinergic antagonists,
which appear to be qualitatively similar to those induced by
benzodiazepine receptor agonists (McNamara and Skelton
1992), almorexant did not impair acquisition of spatial
learning or other abilities required to solve the MWM task
despite the sleep state that almorexant induces in rats at the
dose used. Notably, almorexant had no detrimental effect on
task performance. Almorexant promotes a state of sleep that,
if needed, is immediately and fully reversible (Brisbare-Roch
et al. 2007), although in nocturnal animals, such as rats, the
hypnotic effect of high-dose almorexant given during the day
is lower than its effect at night (Brisbare-Roch et al. 2007). In
our MWM experiments, cued trials served as a control for
sensorimotor function and motivation of the rats, since factors
such as impaired vision (which may prevent rats from using
proximal or distal visual cues), disturbed motor performance
( w h i c hm a yl e a dt oa na b n o r m a ls w i mv e l o c i t ya n di m p a i rt h e
ability to climb the platform), or a lack of motivation (which
may lead to unusual amounts of floating), would compromise
both cued and uncued trials. The finding that almorexant had
no effect on escape latency in control trials suggests that the
effects observed during spatial training are truly related to
learning and memory processes.
Orexinergicinnervationof bothcholinergicandGABAergic
septohippocampal neurons has been suggested as a mechanism
by which the orexin system modulates spatial learning and
memory (Smith and Pang 2005).
Interesting but contradictory results have been reported
on the MWM task with (1) intracerebroventricular infusion
of orexin-A (Aou et al. 2003), (2) lesions in the
septohippocampal system induced by orexin-saporin, a
toxin targeting orexin-B receptors (Smith and Pang 2005),
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Fig. 5 Test of passive avoidance learning: an avoidance memory
retention test was conducted 24 h after rats had been trained once on a
task of passive avoidance learning under either vehicle, almorexant,
combo (both almorexant and scopolamine), or scopolamine treatment.
Avoidance memory retention was intact in both vehicle and
almorexant-treated rats (see text). Asterisks indicate step-through
latency of the respective drug treatment group was statistically
different from step-through latency of the vehicle group. Data are
presented as mean±standard error of the mean with 14–16 rats per
treatment group
152 Psychopharmacology (2010) 212:145–154and (3) infusion of the OX1 receptor antagonist SB-334867
into hippocampal CA1 or dentate gyrus (Akbari et al. 2006,
2007); and on the PA task with (1) intracerebroventricular
infusion of orexin-A (Jaeger et al. 2002; Telegdy and
Adamik 2002), and (2) infusion of SB-334867 into
hippocampal CA1 or dentate gyrus (Akbari et al. 2008).
These studies employed methodologies that differed from
our experiments with respect to: the design of the MWM
protocol (e.g., single- versus multiple-day schedules); the
design of the PA protocol (e.g., step-down versus step-
through type of PA, electric food shock versus air pulse
stimulation); efficacy and selectivity of the test substances
for orexin receptors (agonist versus OX1 or dual OX1/OX2
antagonists); route of administration (local infusion versus
oral treatment); and, in some cases, in the strain of rats
tested (albino versus pigmented). Despite the fact that the
effects reported were heterogeneous and also contradictory,
taken together with our findings, they clearly indicate an
involvement of the orexinergic system in learning and
memory. We report here that rats treated with almorexant
are fully capable of both spatial and avoidance learning.
Whether almorexant could indirectly elicit a beneficial
effect on cognitive functions via its sleep-promoting
properties remains to be further investigated.
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